1
|
Hall A, Abendroth J, Bolejack MJ, Ceska T, Dell’Aiera S, Ellis V, Fox D, François C, Muruthi MM, Prével C, Poullennec K, Romanov S, Valade A, Vanbellinghen A, Yano J, Geraerts M. Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1. ACS Med Chem Lett 2022; 13:1099-1108. [PMID: 35859861 PMCID: PMC9290008 DOI: 10.1021/acsmedchemlett.2c00134] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
![]()
We describe the identification and
characterization of a series
of covalent inhibitors of the C-terminal kinase domain (CTKD) of MSK1.
The initial hit was identified via a high-throughput screening and
represents a rare example of a covalent inhibitor which acts via an
SNAr reaction of a 2,5-dichloropyrimidine with a
cysteine residue (Cys440). The covalent mechanism of action was supported
by in vitro biochemical experiments and was confirmed
by mass spectrometry. Ultimately, the displacement of the 2-chloro
moiety was confirmed by crystallization of an inhibitor with the CTKD.
We also disclose the crystal structures of three compounds from this
series bound to the CTKD of MSK1, in addition to the crystal structures
of two unrelated RSK2 covalent inhibitors bound to the CTKD of MSK1.
Collapse
Affiliation(s)
- Adrian Hall
- UCB, Avenue de l’Industrie, Braine-L’Alleud 1420, Belgium
| | - Jan Abendroth
- UCB Seattle, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States
| | - Madison J. Bolejack
- UCB Seattle, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States
| | - Tom Ceska
- UCB, 216 Bath Road, Slough SL1 3WE, U.K
| | | | | | - David Fox
- UCB Seattle, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States
| | - Cyril François
- NovAliX, Avenue de l’Industrie, Braine-L’Alleud 1420, Belgium
| | - Muigai M. Muruthi
- UCB Seattle, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States
| | - Camille Prével
- UCB, Avenue de l’Industrie, Braine-L’Alleud 1420, Belgium
| | | | - Sergei Romanov
- NANOSYN, 3100 Central Expressway, Santa Clara, California 95051, United States
| | - Anne Valade
- UCB, Avenue de l’Industrie, Braine-L’Alleud 1420, Belgium
| | | | - Jason Yano
- UCB Boston, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | | |
Collapse
|
2
|
MORRIS MC, Bihel F, Diot S, Peter C, Bouclier C, Bricard J, Pellerano M, Hellal M, Prével C. Allosteric Modulators of CDK4 for Lung Cancer Therapeutics. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.00334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Frederic Bihel
- Laboratoire d’Innovation thérapeutique, UMR 7200, CNRS Université de Strasbourg
| | - Sebastien Diot
- Institut des Biomolecules Max Mousseron, CNRS-UMR5247 Université de Montpellier
| | - Clovis Peter
- Laboratoire d’Innovation thérapeutique, UMR 7200, CNRS Université de Strasbourg
| | - Celine Bouclier
- Institut des Biomolecules Max Mousseron, CNRS-UMR5247 Université de Montpellier
| | - Jacques Bricard
- Laboratoire d’Innovation thérapeutique, UMR 7200, CNRS Université de Strasbourg
| | - Morgan Pellerano
- Institut des Biomolecules Max Mousseron, CNRS-UMR5247 Université de Montpellier
| | - Malik Hellal
- Laboratoire d’Innovation thérapeutique, UMR 7200, CNRS Université de Strasbourg
| | - Camille Prével
- Institut des Biomolecules Max Mousseron, CNRS-UMR5247 Université de Montpellier
| |
Collapse
|
3
|
Prével C, Pellerano M, González-Vera JA, Henri P, Meunier L, Vollaire J, Josserand V, Morris MC. Fluorescent peptide biosensor for monitoring CDK4/cyclin D kinase activity in melanoma cell extracts, mouse xenografts and skin biopsies. Biosens Bioelectron 2016; 85:371-380. [PMID: 27203461 DOI: 10.1016/j.bios.2016.04.050] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Revised: 04/15/2016] [Accepted: 04/18/2016] [Indexed: 11/28/2022]
Abstract
Melanoma constitutes the most aggressive form of skin cancer, which further metastasizes into a deadly form of cancer. The p16(INK4a)-Cyclin D-CDK4/6-pRb pathway is dysregulated in 90% of melanomas. CDK4/Cyclin D kinase hyperactivation, associated with mutation of CDK4, amplification of Cyclin D or loss of p16(INK4a) leads to increased risk of developing melanoma. This kinase therefore constitutes a key biomarker in melanoma and an emerging pharmacological target, however there are no tools enabling direct detection or quantification of its activity. Here we report on the design and application of a fluorescent peptide biosensor to quantify CDK4 activity in melanoma cell extracts, skin biopsies and melanoma xenografts. This biosensor provides sensitive means of comparing CDK4 activity between different melanoma cell lines and further responds to CDK4 downregulation by siRNA or small-molecule inhibitors. By affording means of monitoring CDK4 hyperactivity consequent to cancer-associated molecular alterations in upstream signaling pathways that converge upon this kinase, this biosensor offers an alternative to immunological identification of melanoma-specific biomarkers, thereby constituting an attractive tool for diagnostic purposes, providing complementary functional information to histological analysis, of particular utility for detection of melanoma onset in precancerous lesions. This is indeed the first fluorescent peptide biosensor which has been successfully implemented to monitor kinase activity in skin samples and melanoma tumour xenografts. Moreover by enabling to monitor response to CDK4 inhibitors, this biosensor constitutes an attractive companion assay to identify compounds of therapeutic relevance for melanoma.
Collapse
Affiliation(s)
- Camille Prével
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France
| | - Morgan Pellerano
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France
| | - Juan A González-Vera
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France
| | - Pauline Henri
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France
| | - Laurent Meunier
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France
| | - Julien Vollaire
- INSERM U823, Institut Albert Bonniot, F-38000 Grenoble, France; Universite Grenoble Alpes, Institut Albert Bonniot, F-38000 Grenoble, France
| | - Véronique Josserand
- INSERM U823, Institut Albert Bonniot, F-38000 Grenoble, France; Universite Grenoble Alpes, Institut Albert Bonniot, F-38000 Grenoble, France
| | - May C Morris
- Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Université de Montpellier, Faculté de Pharmacie, 15, Av. Charles Flahault, 34093 Montpellier, France.
| |
Collapse
|
4
|
Pellerano M, Naud-Martin D, Peyressatre M, Prével C, Teulade-Fichou MP, Morris M, Mahuteau-Betzer F. TP-2Rho Is a Sensitive Solvatochromic Red-Shifted Probe for Monitoring the Interactions between CDK4 and Cyclin D. Chembiochem 2016; 17:737-44. [PMID: 26946188 DOI: 10.1002/cbic.201500641] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2015] [Indexed: 11/08/2022]
Abstract
Understanding the intricate steps of protein kinase regulation requires characterization of protein-protein interactions between the catalytic subunit, its regulatory partners and the substrate. Fluorescent probes are useful tools with which to study such interactions and to gain insight into their affinities and specificities. Solvatochromic probes, which display changes in their fluorescence emission in response to changes in the polarity of the medium, are particularly attractive. Here we describe conjugation of a switchable fluorescent dye, TP-2Rho, to peptide and protein derivatives of cyclin-dependent kinase 4 (CDK4) and its application to characterization of the interactions between the catalytic subunit of this kinase, its regulatory partner cyclin D1 and a peptide substrate. We demonstrate the sensitivity of TP-2Rho in relation to of those other dyes used for monitoring peptide-protein and protein-protein interactions. Moreover, we show that TP-Rho-labelled peptides can be introduced into living cells to probe endogenous CDK4/cyclin D.
Collapse
Affiliation(s)
- Morgan Pellerano
- Institut des Biomolécules Max Mousseron-IBMM-CNRS-UMR 5247, Faculté de Pharmacie, Université Montpellier 1, 15, avenue Charles Flahault, 34093, Montpellier, France
| | - Delphine Naud-Martin
- Institut Curie, PSL Research University, CNRS, INSERM, UMR9187-U1196, 91405, Orsay, France.,Université Paris Sud, Université Paris-Saclay, CNRS, UMR9187-U1196, 91405, Orsay, France
| | - Marion Peyressatre
- Institut des Biomolécules Max Mousseron-IBMM-CNRS-UMR 5247, Faculté de Pharmacie, Université Montpellier 1, 15, avenue Charles Flahault, 34093, Montpellier, France
| | - Camille Prével
- Institut des Biomolécules Max Mousseron-IBMM-CNRS-UMR 5247, Faculté de Pharmacie, Université Montpellier 1, 15, avenue Charles Flahault, 34093, Montpellier, France
| | - Marie-Paule Teulade-Fichou
- Institut Curie, PSL Research University, CNRS, INSERM, UMR9187-U1196, 91405, Orsay, France.,Université Paris Sud, Université Paris-Saclay, CNRS, UMR9187-U1196, 91405, Orsay, France
| | - May Morris
- Institut des Biomolécules Max Mousseron-IBMM-CNRS-UMR 5247, Faculté de Pharmacie, Université Montpellier 1, 15, avenue Charles Flahault, 34093, Montpellier, France.
| | - Florence Mahuteau-Betzer
- Institut Curie, PSL Research University, CNRS, INSERM, UMR9187-U1196, 91405, Orsay, France. .,Université Paris Sud, Université Paris-Saclay, CNRS, UMR9187-U1196, 91405, Orsay, France.
| |
Collapse
|
5
|
Prével C, Pellerano M, Bihel F, Meunier L, Morris M. New Strategies for Probing and Inhibiting CDK4/cyclin D Hyperactivity in Melanoma. FASEB J 2015. [DOI: 10.1096/fasebj.29.1_supplement.577.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Camille Prével
- Peptides and Amino Acids Institut des Biomolécules Max Mousseron‐UMR5247‐Faculté de PharmacieMontpellierFrance
| | - Morgan Pellerano
- Peptides and Amino Acids Institut des Biomolécules Max Mousseron‐UMR5247‐Faculté de PharmacieMontpellierFrance
| | - Frederic Bihel
- Laboratoire d'innovation thérapeutiqueFaculté de PharmacieUMR CNRS/UdS7200StrasbourgFrance
| | - Laurent Meunier
- Peptides and Amino Acids Institut des Biomolécules Max Mousseron‐UMR5247‐Faculté de PharmacieMontpellierFrance
| | - May Morris
- Peptides and Amino Acids Institut des Biomolécules Max Mousseron‐UMR5247‐Faculté de PharmacieMontpellierFrance
| |
Collapse
|
6
|
Peyressatre M, Prével C, Pellerano M, Morris MC. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel) 2015; 7:179-237. [PMID: 25625291 PMCID: PMC4381256 DOI: 10.3390/cancers7010179] [Citation(s) in RCA: 218] [Impact Index Per Article: 24.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Accepted: 01/12/2015] [Indexed: 12/12/2022] Open
Abstract
Cyclin-dependent kinases (CDK/Cyclins) form a family of heterodimeric kinases that play central roles in regulation of cell cycle progression, transcription and other major biological processes including neuronal differentiation and metabolism. Constitutive or deregulated hyperactivity of these kinases due to amplification, overexpression or mutation of cyclins or CDK, contributes to proliferation of cancer cells, and aberrant activity of these kinases has been reported in a wide variety of human cancers. These kinases therefore constitute biomarkers of proliferation and attractive pharmacological targets for development of anticancer therapeutics. The structural features of several of these kinases have been elucidated and their molecular mechanisms of regulation characterized in depth, providing clues for development of drugs and inhibitors to disrupt their function. However, like most other kinases, they constitute a challenging class of therapeutic targets due to their highly conserved structural features and ATP-binding pocket. Notwithstanding, several classes of inhibitors have been discovered from natural sources, and small molecule derivatives have been synthesized through rational, structure-guided approaches or identified in high throughput screens. The larger part of these inhibitors target ATP pockets, but a growing number of peptides targeting protein/protein interfaces are being proposed, and a small number of compounds targeting allosteric sites have been reported.
Collapse
Affiliation(s)
- Marion Peyressatre
- Institut des Biomolécules Max Mousseron, IBMM-CNRS-UMR5247, 15 Av. Charles Flahault, 34093 Montpellier, France.
| | - Camille Prével
- Institut des Biomolécules Max Mousseron, IBMM-CNRS-UMR5247, 15 Av. Charles Flahault, 34093 Montpellier, France.
| | - Morgan Pellerano
- Institut des Biomolécules Max Mousseron, IBMM-CNRS-UMR5247, 15 Av. Charles Flahault, 34093 Montpellier, France.
| | - May C Morris
- Institut des Biomolécules Max Mousseron, IBMM-CNRS-UMR5247, 15 Av. Charles Flahault, 34093 Montpellier, France.
| |
Collapse
|
7
|
Prével C, Pellerano M, Van TNN, Morris MC. Fluorescent biosensors for high throughput screening of protein kinase inhibitors. Biotechnol J 2013; 9:253-65. [PMID: 24357625 DOI: 10.1002/biot.201300196] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Revised: 07/24/2013] [Accepted: 10/30/2013] [Indexed: 12/11/2022]
Abstract
High throughput screening assays aim to identify small molecules that interfere with protein function, activity, or conformation, which can serve as effective tools for chemical biology studies of targets involved in physiological processes or pathways of interest or disease models, as well as templates for development of therapeutics in medicinal chemistry. Fluorescent biosensors constitute attractive and powerful tools for drug discovery programs, from high throughput screening assays, to postscreen characterization of hits, optimization of lead compounds, and preclinical evaluation of candidate drugs. They provide a means of screening for inhibitors that selectively target enzymatic activity, conformation, and/or function in vitro. Moreover, fluorescent biosensors constitute useful tools for cell- and image-based, multiplex and multiparametric, high-content screening. Application of fluorescence-based sensors to screen large and complex libraries of compounds in vitro, in cell-based formats or whole organisms requires several levels of optimization to establish robust and reproducible assays. In this review, we describe the different fluorescent biosensor technologies which have been applied to high throughput screens, and discuss the prerequisite criteria underlying their successful application. Special emphasis is placed on protein kinase biosensors, since these enzymes constitute one of the most important classes of therapeutic targets in drug discovery.
Collapse
Affiliation(s)
- Camille Prével
- CRBM-CNRS-UMR 5237, Chemical Biology and Nanotechnology for Therapeutics, 1919 Route de Mende, 34293 Montpellier, France
| | | | | | | |
Collapse
|